← 홈

ADC

24개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 24개
ADCBiologicstaleNew York Medical CollegePhase 2

Pv-R CYVE 1 and 2 (Pv-R CYVE 1 and 2)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleNew York Medical CollegePhase 2

Pv-R CYVE-MTX 1 and 2 (Pv-R CYVE-MTX 1 and 2)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleNew York Medical CollegePhase 2

Pv-R-CYM 1 and 2 Group B (Pv-R-CYM 1 and 2 Group B)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleSeagen Inc.Phase 1

SGN-CD19B (SGN-CD19B)

Non-Hodgkin Lymphoma; DLBCL · CD19

#CD19#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 DISCONTINUED

2 / 2 페이지

← 이전다음 →